Pharmaceutical industry embraces cyclic peptides as FDA fast-tracks Merck's candidate
By
Michael McCoy
Summary
The article discusses the growing interest in cyclic peptides within the pharmaceutical industry, highlighted by Merck & Co.'s cyclic peptide enlicitide decanoate being selected for the FDA's new Commissioner's National Priority Voucher pilot program. This program aims to accelerate the review of important drug candidates to just 1-2 months instead of the typical 6+ months. The piece explores how these circular molecules are gaining traction in drug development.
Source
bskyPharmaceutical industry embraces cyclic peptides as FDA fast-tracks Merck's candidatecen.acs.orgKey quotes
· 2 pulledMerck & Co.'s cyclic peptide enlicitide decanoate was one of the first two drug candidates the US Food and Drug Administration selected to receive the new Commissioner's National Priority Voucher in December.
The pilot program is intended to review important drug candidates in just 1–2 months, compared with 6 or more months.
You might also wanna read
Inside the Grey Market Peptide Economy: Regulatory Gaps and Underground Pharmaceutical Infrastructure
This article investigates the parallel pharmaceutical infrastructure built around grey market peptides like BPC-157 and semaglutide. It cont
vectorculture.substack.com·5mo ago
Conflicts of interest threaten integrity of GLP-1 therapy guidance amid rapid adoption
This article discusses the rapid uptake and commercial success of GLP-1 receptor agonists for obesity management, highlighting their clinica
bmj.com·5d ago
Pfizer's Early 1990s Decision to Abandon Promising GLP-1 Therapy Development
The article reveals previously untold history about early GLP-1 drug development in the late 1980s and early 1990s. The author was part of w
statnews.com·5mo ago
Naturopathic Physician Argues Against Peptide Injections, Promotes Body's Natural Production via LCHPMF™ Framework
A naturopathic physician with over 30 years of clinical experience critiques the current peptide trend (BPC-157, CJC-1295, semaglutide, etc.
drjaywrigley.com·5d ago
FDA Announces Loosened Restrictions on Synthetic Peptide Use in Children
The FDA announces it has loosened restrictions on dousing children with synthetic peptides, with the commissioner stating that while the eff
The Onion·2mo ago
FDA Drug Regulator Accused of Targeting Former Business Associate's Pharmaceutical Company
The article discusses a scandal at the FDA involving a top drug regulator who allegedly used his position to target a former business associ
arstechnica.com·7mo agoComments
Sign in to join the conversation.
No comments yet. Be the first.